Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Human FGF-1 in Parkinson's Disease
NCT05493462Phase 1Unknown
- Sponsor
- Zhittya Genesis Medicine
- Start
- Sep 2022
- Primary completion
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fibroblast growth factor 1 in Parkinson's disease (PD), sponsored by Zhittya Genesis Medicine. Primary endpoint: Safety and Tolerability at 12 weeks. Status: unknown.
02
Drugs
fibroblast growth factor 1
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05493462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05493462.